All Stories

  1. Prescribing Under Uncertainty: The Hidden Psychology of Psychiatric Decision-Making
  2. Reviewer recommendations and editorial outcomes in peer review: a longitudinal analysis of agreement and disagreement across review rounds
  3. Changing Your Perspective on Fatal Outcomes in Clozapine-treated patients.
  4. Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia
  5. Reclaiming Pharmacovigilance: Bridging the Evidence–Practice Gap in Psychopharmacology
  6. Co-Created Digital Pretherapy Psychoeducation for Outpatients in Specialized Mental Health Care: Usability Evaluation and Patient Satisfaction Study
  7. A Study in VigiBase of Clozapine Fatal Outcomes in 7,874 Middle-Aged versus 4,380 Young Adults
  8. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase
  9. Psychiatry is not the science of unhappiness
  10. Insomnio: enfoque clínico y terapéutico
  11. Clozapine and Suicide in VigiBase
  12. Fatal Outcomes in Use of Clozapine
  13. The Crisis of Meaning in Aging and the Expansion of Medically Unjustified Euthanasia: A Psychiatric Imperative
  14. Letter to the Editor regarding: “Towards a name change of schizophrenia: positive and negative symptoms disorder (PND)”
  15. On dosing equity, scientific responsibility, and what remains unsaid
  16. Clozapine and Regulatory Inertia: Revisiting Evidence, Risks, and Reform
  17. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature
  18. Perceived Stress and Clinical Insomnia in Primary Care: Associations with Lifestyle and Medication Use
  19. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
  20. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
  21. The Sleep Expectation–Reality Gap: Exploring Discrepancies Between Perceived and Ideal Sleep Duration in Primary Care Patients
  22. Reflections on the Potential and Risks of AI for Scientific Article Writing after the AI Endorsement by Some Scientific Publishers: Focusing on Scopus AI
  23. Clozapine pharmacovigilance in Croatia: underreporting of specific adverse drug reactions and excellent reporting of suicide attempts
  24. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
  25. A case of recurrent priapism during prolonged clozapine administration
  26. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data
  27. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety
  28. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature
  29. Exploring the Relationship Between Psychological Constructs and Decision-Making Preferences in Psychiatric Outpatients
  30. Implications of psychological reactance for clinical practice in psychiatry including a systematic review.
  31. Investigating in VigiBase® over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia
  32. Psychoeducational group interventions for adults diagnosed with attention-deficit/ hyperactivity disorder: a scoping review of feasibility, acceptability, and outcome measures
  33. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK
  34. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database
  35. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance
  36. Will ChatGPT3 Substitute for us as Clozapine Experts?
  37. Guía internacional Para una dosificación más Segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la Proteína C Reactiva y los niveles de clozapina
  38. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance
  39. Psychiatric Patients’ Perceived Health Control and Reactance: Implications for Medication Adherence
  40. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
  41. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)
  42. Escaping the Long Shadow Cast by Agranulocytosis
  43. Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in VigiBase
  44. NURSING STUDENT’S VIEWS ON THE DUTY OF CARE: A CROSS-SECTIONAL STUDY IN TWO COUNTRIES
  45. Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review
  46. Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase
  47. Telepsychiatry: The future is already present
  48. Psychometric Properties of the WHO-5 Well-Being Index among Nurses during the COVID-19 Pandemic: A Cross-Sectional Study in Three Countries
  49. Clozapine and the risk of haematological malignancies
  50. An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine
  51. Evaluating the Effect of a Telepsychiatry Educational Program on the Awareness, Knowledge, Attitude, and Skills of Telepsychiatry Among Spanish Psychiatrists during COVID-19 Pandemic
  52. An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s
  53. The duty to care and nurses' well-being during a pandemic
  54. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase
  55. Promoting safer clozapine dosing in the Americas
  56. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
  57. The Mediating Role of Resilience in the Relationship between Perceived Stress and Mental Health
  58. Miocarditis inducida por la clozapina: estudios animales pero no clínicos
  59. Clozapine-associated myocarditis in the World Health Organization’s pharmacovigilance database: Focus on reports from various countries
  60. Clinimetric Criteria for Patient-Reported Outcome Measures
  61. Exploring patterns in psychiatric outpatients’ preferences for involvement in decision-making: a latent class analysis approach
  62. Effect of necessity‐concern framework and polypharmacy on treatment adherence in psychiatric patients. Comparing an Argentinian with a Spanish sample
  63. An update on the complex relationship between clozapine and pneumonia
  64. Effects of a peer co-facilitated educational programme for parents of children with ADHD: a feasibility randomised controlled trial protocol
  65. Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics
  66. Patient-reported well-being: psychometric properties of the world health organization well-being index in specialised community mental health settings
  67. Assessment of shared decision-making in community mental health care: Validation of the CollaboRATE
  68. Psychometric properties of the Five‐item World Health Organization Well‐being Index used in mental health services: Protocol for a systematic review
  69. The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase
  70. A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology
  71. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics
  72. The necessity‐concern framework in the assessment of treatment adherence of psychiatric patients and the role of polypharmacy in a Spanish sample
  73. Data From the World Health Organization’s Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions
  74. Development and validation of the Patient’s Health Belief Questionnaire on Psychiatric Treatment
  75. Effectiveness and cost-effectiveness of a multicomponent intervention to improve medication adherence in people with depressive disorders - MAPDep: a study protocol for a cluster randomized controlled trial
  76. Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: a comparison among outpatient samples recruited in Spain, Argentina, and Venezuela
  77. The Art of Pharmacotherapy
  78. Antipsychotics and driving ability
  79. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach
  80. Seguridad vial y toxicidad conductual por psicofármacos
  81. Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on Adherence
  82. Validity of the Control Preferences Scale in patients with emotional disorders
  83. Treatment-related decisional conflict in patients with depressive and anxious disorders
  84. Preferencias por las decisiones compartidas en pacientes con depresión
  85. Coste-utilidad de asenapina frente a olanzapina para el tratamiento de los episodios maniacos de pacientes con trastorno bipolar tipo I
  86. Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence
  87. To what extent is treatment adherence of psychiatric patients influenced by their participation in shared decision making?
  88. Preferences for participation in shared decision making of psychiatric outpatients with affective disorders
  89. Estrategias de manejo de los antidepresivos desde la perspectiva de los pacientes: luchando interna y externamente
  90. Editorial [Hot Topic: Compliance, Adherence and Concordance in Medicine Taking of Psychiatric Patients (Guest Editor: Carlos De las Cuevas)]
  91. Antidepressant Use in Early Pregnancy
  92. Lithium Use During Early, Late Pregnancy, and Breastfeeding
  93. Psychomotor performance and fitness to drive: The influence of psychiatric disease and its pharmacological treatment
  94. Versión española consensuada de la Severity of Dependence Scale (SDS)
  95. Attitudes toward psychiatric drug treatment: the experience of being treated
  96. Are psychotropics drugs used in pregnancy?
  97. Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy
  98. Telepsychiatry: Psychiatric consultation through videoconference patients' perception and satisfaction
  99. Telepsychiatry: Psychiatric consultation through videoconference clinical results
  100. Polypharmacy in psychiatric practice in the Canary Islands
  101. Evaluación cualitativa en teledermatología: resultados del proyecto piloto Telemedicina 2000
  102. Benzodiazepines: more "behavioural" addiction than dependence
  103. Burnout en los profesionales de la atención a las drogodependencias
  104. Telepsiquiatría: utopía o realidad asistencial
  105. Variations in antidepressant prescribing practice: clinical need or market influences?